Instrument Inactif

Communiqués Silence Therapeutics plc London S.E.

Actions

SLN

GB00B9GTXM62

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	27/06	BU
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration	24/06	BU
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)	20/06	BU
Silence Therapeutics to Present at Jefferies Global Healthcare Conference	30/05	BU
Silence Therapeutics : Condensed consolidated income statement (unaudited) - Form 6-K	16/05	PU
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress	16/05	BU
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference	30/04	BU
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors	29/04	BU
Silence Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	15/04	PU
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	08/04	BU
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	13/03	BU
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)	13/03	BU
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024	28/02	BU
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	26/02	AQ
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	23/02	BU
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement	05/02	BU
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01	BU
Gubra concludes the research agreement with UK Biotech	26/01	AQ
Silence Therapeutics : Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer - Form 6-K	01/12	PU
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments	01/12	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Silence Therapeutics plc London S.E.

Actions

SLN

GB00B9GTXM62

Communiqués

Filtres